Swiss drugmaker Roche has revealed that latest studies indicate Avastin may be helpful in lung cancer patients when given in combination with gemcitabine-cisplatin chemotherapy
The study showed that such a combination extended the time patients are able to survive without lung cancer progression. The "Avail" trial found that patients with advanced non-small cell lung cancer (NSCLC) were able to live 30 percent longer without disease progression when Avastin was given in combination with other drugs.
Advertisement
"Avail confirms for the second time that Avastin provides important clinical benefits and the longest survival reported for patients with advanced non-squamous NSCLC," said principal investigator Christian Manegold of Heidelberg University in Mannheim, Germany.
The details of the study were presented at the European Society of Medical Oncology in Stockholm.
Source: Medindia
RAS/L
Source: Medindia
RAS/L
Mesothelioma - Animation
Animation on mesothelioma - a form of lung cancer, that explains about the condition, its risk factors, diagnosis and treatment
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
Researchers create needle-free Zika vaccine patch, using HD-MAP tech, aiming to protect against fatal virus spread by mosquitoes.
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.
Human apotransferrin injected to mice models suffering from intracerebral hemorrhage was found to mitigate the serious effects of stroke.